Healthcare · Pharmaceuticals & Biotechnology
Dishman Carbogen Amcis Ltd is an Indian multinational pharmaceutical company specialized in the manufacture of active ingredients and contract development and manufacturing. Dishman employs over 1,000 people worldwide and is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE).
Source: Wikipedia
| Fiscal year | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Total income (before exceptional items) | 316† | 433† | 390† | 456† | 370† |
| Net profit | -38 | -10 | -76 | -59 | -32† |
₹ Crore. † Summed from the four quarterly filings of that fiscal year.
Current board roster from exchange filings. Director remuneration is not in our data, so it isn't shown.
| Name | Designation | Term end |
|---|---|---|
| Arpit Janmejay Vyas | Executive Director | June 30, 2026 |
| Deohooti Janmejay Vyas | Executive Director | June 30, 2026 |
| Hemantkumar Jayantiprasad Bhatt | Independent Director | June 30, 2026 |
| Kulin Nalinkant Shah | Independent Director | June 30, 2026 |
| Margie Parikh | Independent Director | June 30, 2026 |
| Dhaval Rameshchandra Shah | Non-Executive Director | June 30, 2026 |
Key management names, their remuneration, subsidiaries and brand listings are not in the exchange filings we ingest yet, so they are not shown here rather than estimated.
